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Chronic inﬂammation plays a pivotal role in atherosclerosis. We hypothesized that combining overweight and a greater genetic
capacitytoproduce IL-6predicted byIL-6 genepromoterpolymorphismatposition-174(G→C)mayallowtoidentifyindividuals
exhibiting higher IL-6 and C-reactive protein (CRP) concentrations with a higher risk of atherosclerotic events (AE). The
occurrence of AE was analyzed with respect to body mass index, IL-6 gene promoter polymorphism at position -174 (G→C),
and other relevant risk factors, retrospectively, in 217 renal transplant recipients and, prospectively, in 132. Circulating IL-6
concentrations were closely related to BMI (r = 0.55, P = .0005). In overweight patients, serum IL-6 concentration was found
to be signiﬁcantly lower in C carriers than in GG patients (4.2 [1.0–5.1] versus 7.3pg/mL [4.4–100]; P = .025). The incidence
of AE was higher in overweight GG patients (29.5% versus 10.1%; P = .0003). In multivariate analysis, overweight-GG had an
increased risk to develop AE (HR 2.96 [95% CI 1.09–8.04], P = .034 in the retrospective cohort, and HR 2.99 [95% CI 0.92–9.33],
P = .069 in the prospective cohort). All these data are consistent with a role for both genetic and environmental determinants of
inﬂammation(white adipose tissue mass) in the development of AE in renal transplanted patients.
1.Introduction
Chronic inﬂammation plays a pivotal role in the pathogen-
esis of atherosclerosis. For instance, elevated plasma con-
centrations of C-reactive protein (CRP), a sensitive marker
of underlying inﬂammation, have been shown to predict an
increased risk of future cardiovascular (CV) outcomes in the
general population [1]. Our group recently reported that
highCRPlevelswerealsopredictiveofcoronaryheart disease
in renal transplant recipients (RTRs) [2]. Circulating CRP
levels are under the control of IL-6 secretion [3]. As a result,
the capacity to produce CRP, and subsequently inﬂamma-
tion, depends at least in part on the capacity to produce
IL-6. We recently demonstrated that IL-6 concentrations are
in part genetically determined and varied with IL-6 gene
promoter polymorphism at position -174 (G→C) in renal
transplantrecipients[4].Moreover,ithasbeendemonstrated
that white adipose tissue—that contains adipocytes—is an
important source of basal IL-6 secretion [5].
We hypothesized that combining overweight and a great-
er genetic capacity to produce IL-6 predicted by IL-6 gene
promoterpolymorphism atposition-174 (G→C) mayallow
to identify a population exhibiting higher IL-6 and CRP con-
centrations and carrying a higher risk of atherosclerotic
events (AEs).2 Journal of Transplantation
2.Materialsand Methods
2.1. Study Design and Populations. We analyzed two groups
of patients to assess whether IL-6 gene promoter polymor-
phism at position -174 (G→C) may be a risk factor for the
later development of AE independently of other risk factors.
The two cohorts have been previously described [4].
Brieﬂy, we ﬁrst conducted a nested genetic study in a retro-
spective cohort of 217 patients. These patients were trans-
planted between January 1990 and June 2001.
Second, we studied a prospective cohort of 132 consecu-
tive patients transplanted between July 2001 and December
2004 in our center.
Age, gender, BMI (weight [Kg]/size2 [m2]), past history
of cardiovascular disease (CVD), hypertension, prior renal
transplantation, CMV donor/recipientstatus, HLAcompati-
bility, and panel-reactive antibodies (PRAs) were analyzed as
covariates. Dialysis mode (none, hemodialysis, or peritoneal
dialysis) and its duration prior to transplantation were re-
corded. All parameters were collected at the transplant time.
Due to the design of the ﬁrst study [4], patients with pre-
transplant diabetes had been excluded.
Approval was obtained from the Besanc ¸onethicalcom-
mittee for these studies. Informed consent was provided ac-
cording to the Declaration of Helsinki.
2.2. Cardiovascular Risk Factors. Age, gender, weight, size,
blood pressure, hemodialysis duration before transplanta-
tion, smoking status, past history ofAE, immunosuppressive
treatment (use of calcineurin inhibitors), and diﬀerent bio-
logic parameters were assessed upon inclusion.
2.3. Deﬁnition of Atherosclerotic Events
One has the following:
(i) coronary heart disease: Myocardial infarction, coronary




(ii) stroke/cerebrovascular disease: Both nonhemorrhagic
and hemorrhagic strokes and carotid endarterectomy;
(iii) abdominal aortic or lower extremity arterial disease:
Abdominal aortic repair, lower extremity amputation, and
intermittent claudication conﬁrmed by Doppler or arteriog-
raphy ﬁndings.
2.4. DNA Extraction and Analysis of IL-6 Gene Promoter Poly-
morphism at Position -174 (G→C). Genomic DNA (gDNA)
was extracted from white blood cells using standard salting
out procedure [6]. Analysis of the IL-6 gene promoter loci
was then studied using a PCR-based genotyping assay [7].
Methods have been previously described in details [4].
2.5. Functional Validation of the IL-6 Gene PromoterPolymor-
phism. The functional eﬀects of IL-6 gene promoter poly-
morphism were analyzed by measuring serum levels of IL-6,
6 months posttransplant in 36RTR (12 carrying the CC
genotype, 12 the GC genotype, and 12 the GG genotype).
None of the patients experienced either acute rejection or
infections at time of serum collection. Interleukin-6 was
measured with high-sensitivity ELISA kits (Quantikine HS
IL-6 Immunoassay, #HS600B, R&D Systems, Lille, France)
according to manufacturer’s instructions. Brieﬂy, the proﬁle
of IL-6 secretion was determined according to the genotype
of the promoter. Three diﬀerent possible genotypes at the -
174 position of the IL-6 gene promoter can then be deﬁned
and associated with a high (G/G), medium (G/C), or low
(CC) secretion proﬁle [8] .B e c a u s eI L - 6i sr e c o g n i z e da st h e
main inducer for hepatic CRP synthesis [9], CRP (high-
sensitivity determination) serum levels were measured by
nephelometry (Beckman Coulter, Villepinte, France) in all
patients.
2.6. Statistical Analysis. Arithmetic mean was calculated and
expressed as ± standard deviation (SD). Circulating IL-
6 concentrations were not normally distributed and their
values in the three diﬀerent genotypes were compared using
the Kruskal-Wallis test. Diﬀerences in circulating IL-6 values
between GG and C carriers were evaluated by the Mann-
Whitney test. For normally distributed variables, C carriers
and GG patients were compared using the χ2 test for
dichotomic variables and the Student t-test for continuous
variables. Hardy-Weinberg equilibrium was assessed for
the genotype distribution. Relationships between numerical
variables were evaluated with the Spearman/Pearson rank
test. Using log-rank tests on Kaplan Meier nonparametric
estimates of the survival without atherosclerotic events
distribution, we selected variables with a P-value lower than,
or equal to, .20. The selected variables were included into a
Cox proportional hazard model, and a backward stepwise
selection process was performed, this time at a classical
α = 0.05. All baseline data were assessed on the transplant
day. BMI was separated into two classes (<25 or ≥25Kg/m2
corresponding to overweight patients). Results are expressed
as Hazard ratio (HR)and 95% conﬁdenceinterval (CI),with
a P-value testing the null hypothesis: HR = 1. Therefore
when P-value is less than .05, HR is signiﬁcantly diﬀerent
from 1. Assumptions of Cox models (log-linearity and
proportionality of risk in time) were met in this analysis.
Analysis was performed on Statview 5 (SAS institute Inc.).
3.Results
3.1. Study Population
3.1.1. Retrospective Cohort. The cohort of 217 patients was
followed for a mean duration of 11.8 ± 5.8y e a r sp o s t -
transplant. Mean follow-up was similar in patients with the
diﬀerent genotypes. There was no diﬀerence in the timing
of transplants between the diﬀerent genotypes (data not
shown). Meanagewas43±13yearsand139RTR(64%)wereJournal of Transplantation 3
men. Hypertension was present in 156 RTR (72%). Mean
dialysisdurationwas20±17months. Allthepatientsbutﬁve
were Caucasians.
3.1.2. Prospective Cohort. One hundred and thirty two
patients were studied with a mean follow-up of 6.1 ± 2.8
years. Five patients died during follow-up and four lost their
graft. There was no diﬀerence in the timing of transplants
between the diﬀerent genotypes (data not shown). Mean age
was47±14yearsand86RTR(65%)weremen.Hypertension
was present in 99RTR (75%). Mean dialysis duration was
19 ± 13 months.
3.2. Interleukin-6 Gene Promoter-174 Genotype Frequencies in
Renal Transplant Recipients
3.2.1. Retrospective Study. Ninety ﬁve patients (43.8%) were
GG homozygotes (wild type), 92GC heterozygotes (42.4%),
and 30 (13.8%) CC homozygotes (mutant) (Table 1). There
was no diﬀerence in pretransplant characteristics, acute graft
rejection episodes, and cumulative dose of steroid during
ﬁrst year of transplant between patients with the diﬀerent
genotypes (Table 2). The proportion of GG homozygotes
was similar in patients with and without overweight (46%
versus 43%). The observed allele frequencies were in Hardy-
Weinberg equilibrium.
3.2.2. Prospective Study. The allele frequencies were similar
in the prospective cohort (GG, 42.7%; GC, 45.9%; CC,
11.4%) (Table 1). Nevertheless, in this cohort, C carriers
patients were older than patients with the G allele (49 ±
13 versus 47 ± 14; P = .037) (Table 2). Sex ratio was
also diﬀerent with more females in C carriers than in GG
allele carriers (47% versus 33%; P = .042) (Table 2). The
proportion of GG homozygotes was similar in patients with
and without overweight (40% versus 44%). The observed
allele frequencies were in Hardy-Weinberg equilibrium.
3.3. Relationship between the IL-6 Gene Promoter-174 Geno-
type, Circulating IL-6, and Body Mass Index in Renal
Transplant Recipients. Circulating IL-6 concentrations were
closely related to BMI (r = 0.55, P = .0005). There was
a trend toward alinear increase in serum IL-6 concentrations
from the CC genotype to the GG genotype (median values
and ranges were, resp., 2.77 [1.02 to 9.26], 3.48 [1.11 to
76.85], and 4.19pg/mL [2.02 to 100] in CC, GC, and GG
carriers; P = .09). When analysis was restricted to patients
with overweight, serum IL-6 concentration was found to be
signiﬁcantly lower in C carriers than in GG patients (4.2
[1.0–5.1]versus7.3pg/mL [4.4–100];P = .025).By contrast,
in patients without overweight, IL-6 levels were quite similar
in C carriers than in GG patients (2.2 [1.4–9.3] versus
2.7pg/mL [1.1–17.8]; P = .27).
CRP levels were assessed in the 217 patients of the ret-
rospective study. Posttransplant CRP concentrations were
lower in C carriers (n = 122) than in GG patients (n = 95)
(3.2 ± 1.6, 4.1 ± 2.2, and 4.4 ± 2.1mg/L in CC, GC, and GG
patients, resp.; P = .03). Similar results were observed in
the prospective cohort (n = 77C carriers and n = 55GG
patients) (3.0±1.5, 4.2±2.3, and 4.7±2.4mg/L in CC, GC,
and GG patients, resp.; P = .02).
Overweight GG patients (n = 27 and 17, resp., in ret-
rospective and prospective cohorts) had higher CRP levels
than other categories of patients (4.9 ± 2.3v e r s u s3 .8 ± 2.7;
P = .015).
These resultsconﬁrmed a greaterdegreeofinﬂammation
in overweight GG patients. As a consequence, we compared
the incidence of AE between overweight GG patients and the
rest of the population.
3.4. Relation between IL-6 GenePromoterPolymorphism-174,
Body Mass Index, and Cardiovascular Events
3.4.1. Retrospective Cohort. Mean follow-up was 11.8 ± 5.8
years.
Thirty two patients (14.7%) experienced atherosclerotic
complications during the study period (Coronary Heart Dis-
ease, 24; CerebroVascular Disease, 3; Peripheral Vascular
Disease, 5).
The cumulated incidence of AE was higher in patients in
overweight GG patients(33%versus12%;P = .006)(Table 3
and Figure 1).
In univariate analysis, older age (P = .002), male gender
(P = .031), and a past history of AE (P = .004) were also
associated with AE.
GG patients did not carry an increased risk of AE (P =
.251).
In multivariate analysis, olderpatients (HR1.07 [95% CI
1.03–1.12] with each one year increase in age, P = .001) and
overweight-GG patients (HR 2.96 [95% CI 1.09–8.04], P =
.034) had an increased risk of AE (Table 4).
3.4.2.ProspectiveCohort. Meanfollow-upwas 6.1±2.8years.
Seventeen patients (11.8%) experienced atherosclerotic
complications during the study period (Coronary Heart
Disease, 9; CerebroVascular Disease, 3; Peripheral Vascular
Disease, 5).
The cumulated incidence of AE was higher in patients in
overweight GG patients (33% versus 9%; P = .031) (Table 3
and Figure 1).
In univariate analysis, older age (P = .026), male gender
(P = .053), and a past history of AE (P = .004) were also
associated with AE. GG patients did not carry an increased
risk of AE (P = .251).
In multivariate analysis, older patients (HR 1.07 [95%
CI 1.03–1.12] with each one year increase in age, P = .001)
and those with a past history of AE (HR 3.88 [95% CI 1.09–
11.35], P = .042) had an increased risk of AE. There was
a trend towards an increased risk of AE in overweight GG
patients (HR 2.99 [95% CI 0.92–9.33], P = .069) (Table 4).
3.4.3. Overall Cohort. The cumulated incidence of AE was
higher in patients in overweight GG patients (29.5% versus
10.1%; P = .0003) (Table 3) .T h er a t eo fA Ew a ss i m i l a r
in overweight patients than in patients with normal weight
(19% versus 13.1%; P = .205). In patients with normal4 Journal of Transplantation
Table 1: -174genotype frequencies in renal transplant recipients.
Genotype Retrospective cohort Prospective cohort
Number [%] Number [%]
GG 95 43.8% 55 41.7%
C carriers 122 56.2% 77 58.3%
Total 217 100% 132 100%
Table 2: Characteristics of patients with the diﬀerent IL-6
-174 gene promoter genotypes.
Retrospective cohort Prospective cohort
GG C carriers GG C carriers
n = 95 N = 122 n = 55 N = 77
Age 45 ± 12 45 ± 12 47 ± 14 49 ± 13
Sex ratio (% male) 64% 64% 72% 53%
Pretransplant BMI (kg/m2) 23.7 ± 4.1 23.4 ± 4.6 23.9 ± 4.0 24.0 ± 4.5
Past history of cardiovascular disease 4.0% 3.9% 10.0% 12.7%
Acute rejection 22% 20% 18% 16%
BMI: body mass index.
weight, the cumulative incidence of AE was similar in C car-
riers and GG patients (12.4% versus 14.8%; P = .703).
In univariate analysis, older age (P<. 0001), male gender
(P = .005), and a past history of AE (P<. 0001) were also
associated with AE. GG patients did not carry an increased
risk of AE (P = .251).
In multivariate analysis, older age (HR 1.06 [95% CI
1.02–1.09] with each one year increase in age, P = .0005),
male gender (HR 2.83 [95% CI 1.22–6.55], P = .016), and
a past history of AE (HR 6.34 [95% CI 1.61–18.35], P =
.008) were independent risk factors for AE. Overweight GG
patients had also an increased risk of AE (HR 3.08 [95% CI
1.33–7.13], P = .009) (Table 4).
4.Discussion
Here, we reported that the GG genotype of the IL-6 gene
promoter -174, associated with a higher capacity to produce
IL-6, is an independent risk factor for AE in overweight
transplanted patients, but not in patients with standard
weight. We also showed that IL-6 concentrations were
increased only inthe same subset ofpatientswith overweight
and carrying the GG genotype of the IL-6 gene promoter
at position -174. This result is probably due to the fact
that white adipose tissue is a major source of basal IL-
6s e c r e t i o n[ 5]. Thus, only the combination of a greater
genetically determined capacity to produce IL-6 and of an
increased mass of IL-6-producing tissues seems to result in
higher circulating IL-6 levels. Concordant with this result,
we also found higher posttransplant CRP concentrations
in overweight patients with the IL-6 gene promoter GG
genotype. Methodological standardization is mandatory in
SNPs studies: a plausible hypothesis, the biological relevance
of the polymorphism, and a conﬁrmation of the results in a
separate independent cohort are indispensable prerequisite
in such studies [10] .A l lt h i se s s e n t i a lc o n d i t i o n sa r em e t
in this study. Collectively, all these data are consistent with
a role for both genetic and environmental determinants of
inﬂammation in the development of AE.
The relationship between obesity, metabolic syndrome,
and inﬂammation has already been described. Riikola et al.
recently reported a statistical link between IL-6 gene pro-
moter polymorphism -174G/C and several metabolic risk
factorsinmen.IndeedGG genotypeisassociatedwithhigher
serum total cholesterol and LDL cholesterol in male [11].
This could be explained by an impaired reverse cholesterol
transport in vivo due to inﬂammation as described in the
study by McGillicuddy et al. [12]. Wajchenberg et al.
demonstrated that low-grade inﬂammation is the cause of
developing insulin resistance, metabolic syndrome, and en-
dothelial dysfunction in obesity, through a chronically acti-
vated inﬂammatory state of the adipose tissue [13]. More-
over, we recently showed that the IL-6 gene promoter
polymorphism -174 was associated with new-onset diabetes
after transplantation [4]. All these ﬁndings add to the recent
notion of adipose tissue as playing a central role in lipid
and glucose metabolism. Adipose tissue produces a large
number of cytokinessuch as IL-6 and thisendocrinecapacity
is enhanced in obese subjects [14]. This could explain
low-grade inﬂammation in this population which is the
angular stone of metabolic syndrome and cardiovascular
diseases associated with obesity. Our results are in concor-
dance with this phenomenon. In regards of these studies, we
could hypothesize that the relationship between obesity and
atherosclerotic events in transplanted patients is mediated
by the individual degree of inﬂammation at least in part
genetically determined.
Our work highlights the need to take into account plau-
sible interactions between genetic background and environ-
mental conditionsin geneticassociation studies. Geneticfac-
tors are likely to aﬀect the occurrence of numerous common
diseases. Nevertheless, genes operate in complex pathways
with not only gene to gene but also gene to environmental
factor interactions [15]. In the speciﬁc case of IL-6, weJournal of Transplantation 5
Table 3: Incidence of atherosclerotic events (AEs) in the retrospective, prospective, and overall cohort according to IL-6
-174 genotype and
body mass index (BMI).
All patients Overweight patients carrying the GG genotype Other patients P
Retrospective cohort (n = 217) 14.7% (n = 32) 33% (n = 9) 12% (n = 23) .006
Prospective cohort (n = 132) 11.8% (n = 17) 33% (n = 3) 9% (n = 12) .031

































































Figure 1: Survival without atherosclerotic events in the two cohorts.
showed that even when we showed that the IL-6 gene pro-
moterpolymorphism inﬂuencesIL-6levelsinthewhole RTR
population, the diﬀerence is mainly explained by the dif-
ference observed in overweight patients. When considering
both the GG genotype of IL-6 gene promoter at position
-174 and overweight, we deﬁned a phenotype-genotype
association with both biological and clinical relevance. Thus,
we believe that an integrative approach associating both
geneticand nongenetic factors is required to predict the abil-
ity to generate variable amounts of a speciﬁc gene-product
and study its eﬀects.
A selection bias is likely in the retrospective study. All the
results indicate that we included low-risk patients regarding
risks of AE, graft failure, and death. As a consequence,
a survival bias could not be totally excluded. A diﬀerential
rateofgraft and patientsurvival orDNAavailabilitybetween
patients with the C or G alleles may also have inﬂuenced our
results. Nevertheless, all these limitations should favor the
null hypothesis and not contribute to a false positive result.
Moreover, due to the design of the initial study, patients with
pretransplant diabetes were excluded. Whether our results
are applicable to diabetic patients remains to be determined.
Bythenatureoftherecruitmentprocess,clinicalinformation
obtained prospectively is usually of higher quality than
retrospective data and our retrospective study can only
be used to generate hypotheses that have to be validated
in a prospective cohort. We validated the circulating IL-6
levels towards the genotype of IL-6 gene polymorphism only
with patients from the retrospective cohort (15GG, 15GC,
15CC).Indeed, this validation has already been described by
Fishmanetal.[8].Ouraimwastodemonstratethattheeﬀect
of the SNP was also eﬀective in transplanted patients under
immunosuppressive drugs. We performed the validation in
the retrospective cohort. There is no reason to suspect that
the association could be diﬀerent in the second cohort re-
ceiving the same immunosuppressive drugs.
Analysis of our prospective cohort conﬁrmed the results
obtained in the retrospective cohort. Yet, association of the
C allele with atherosclerotic events is hardly signiﬁcant in
the prospective cohort (P = .069). The prospective cohort
was smaller (n = 132) and the mean period of follow-
up was only 6.1 ± 2.8 years. These are probably the
main reasons why the association between GG genotype in
overweight and atherosclerotic events (AEs) did not reach
signiﬁcance. It is also likely that this cohort carried a lower
risk (younger age, higher percent of females). Nevertheless,
it is important to note that we observed a same trend in the
two cohorts allowing us to pool our data. When we pooled
the two cohorts (retrospective and prospective), overweight
GG genotype associated with AE reached signiﬁcance (HR
3.08 [95% CI 1.33–7.13], P = .009).
We did not directly compared GG overweight with
GG nonoverweight patients. These comparisons are made
through the analysis of overweight on AE. Overweight was6 Journal of Transplantation
Table 4:Risk factors ofcardiovascular events in the retrospective, prospective, and overallcohort (multivariate analysisexpressed in Hazard
ratio).
HR IC 95% P
Retrospective cohort
Age >45y.o 1.07 [1.03–1.12] .001
Overweight + IL-6 GG genotype 2.96 [1.09–8.04] .034
Prospective cohort
Age >45 y.o 1.07 [1.03–1.12] .001
Past history of CVE 3.88 [1.09–11.35] .042
Overweight + IL-6 GG genotype 2.99 [0.92–9.33] .069
Overall cohort
Age >45y.o 1.06 [1.03–1.09] .0005
Male gender 2.83 [1.22–6.55] .016
Overweight + IL-6 GG genotype 3.08 [1.33–7.13] .009
not associated with AE. This could be explained by the fact
that a large part of the inﬂuence of overweight on AE could
be due to the increased secretion of IL-6 by fat tissue in
genetically predisposed patients (i.e., those carrying the GG
genotype).
Finally, our results highly suggest that IL-6 production
capacityinﬂuencesthedevelopmentofAEafterkidneytrans-
plantation in overweight patients. The IL-6 gene promoter
polymorphismatposition-174mayserveasageneticmarker
tohelpphysicians indeterminingrecipientrisk proﬁleandin
optimizing pre-and posttransplant treatment strategies.
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